BMG637AM1024 - Common Stock
Myovant Sciences Ltd
NYSE:MYOV (3/9/2023, 7:04:00 PM)
After market: 26.98 0 (0%)26.98
-0.01 (-0.04%)
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. The firm is focused on redefining care for women and for men through science, medicines and transformative advocacy. The Company’s two products include ORGOVYX (relugolix 120 mg), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer; and MYFEMBREE, a once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids. The Company, through its subsidiary, Myovant Sciences GmbH develops supplemental New Drug Application for once-daily MYFEMBREE for the management of moderate to severe pain associated with endometriosis and being assessed for contraceptive efficacy in women ages 18-35 years who are at risk for pregnancy. The company develops Relugolix for the treatment of men with advanced prostate cancer. The firm is also developing MVT-602, which has completed a Phase IIa study for the treatment of female infertility.
Myovant Sciences Ltd
Ste 1 3rd Fl, 11/12 St. James's Square
London SW1Y 4LB
P: 442074003351.0
CEO: David Marek
Employees: 579
Website: http://myovant.com/
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. ("Myovant" or the "Company") (NASDAQ: MYOV). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. ("Myovant" or the "Company") (NASDAQ: MYOV). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. ("Myovant" or the "Company") (NASDAQ: MYOV). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. ("Myovant" or the "Company") (NASDAQ: MYOV). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. ("Myovant" or the "Company") (NASDAQ: MYOV). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. ("Myovant" or the "Company") (NYSE: MYOV). Such...
Here you can normally see the latest stock twits on MYOV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: